Just over two years into Anderson's tenure, Bayer's board has decided to extend his contract by three years to 31st March, 2029, with company chairman Norbert Winkeljohann saying: "We're starting to ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives, namely ...

Healthinote is a smartphone-based toolkit designed to boost patient engagement by providing personalised, trustworthy, and ...

Sanofi has been granted a speedy review from the FDA for a gene therapy for geographic atrophy (GA), a complication of age-related macular degeneration (AMD), as it prepares to test it in a clinical ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

Hong Kong-based Sino Biopharm, which took its stake in LaNova when it participated in the company's $42 million financing ...

"Given the Supreme Court's ruling, HHS is now permitted to move forward with a portion of its RIF. Accordingly, you are ...

Hopes have risen for a new treatment option for a rare and severe form of childhood epilepsy, Dravet syndrome, after Biogen and Stoke Therapeutics reported new data for their recently partnered ...

Together, these policies signal a new era of pricing accountability and regulatory oversight, with significant implications for drug development strategies, market access, and patient affordability.

The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed the role that innovative medicines can play in driving advances in ...

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new 10-year plan for the NHS. The three over-arching themes are already ...

The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.